EMA counts the cost of Brexit in lost staff and narrower wor...

Merck’s last-resort antibiotic Recarbrio nears EU approval

EMA resolves dispute over pricey Canary Wharf tenancy

Alexion’s Soliris follow-up Ultomiris snares EU approval

Mitsubishi Tanabe pulls ALS drug from EMA assessment

Mitsubishi Tanabe Pharma has withdrawn its EU application for ALS drug Radicava (edaravone), citing ‘unwarranted’ additional data requirements from the EMA.

EMA set for official move from London on 1 March

The European Medicines Agency (EMA) has officially taken over its new building in Amsterdam in preparation of its move to the Dutch capital from London.